Aberrant erythrocyte rigidity in JAK2(V617F) myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage.

JAK2V617F mutation causes erythrocyte stiffening, leading to abnormal clot formation and increased risk of thrombosis and hemorrhage in MPNs.

• Why it matters: Understanding how erythrocyte mechanics contribute to clot pathology addresses a critical gap in managing thrombotic and bleeding complications in myeloproliferative neoplasms.
• What they did: The study used lineage-specific knockin mice and human samples to analyze clot formation, revealing that JAK2V617F induces intrinsic erythrocyte stiffening through membrane and cytoskeletal alterations, impairing clot contraction.
• The result: Rigid erythrocytes promote larger, unstable thrombi that can cause both occlusion and bleeding, highlighting erythrocyte mechanics as a potential therapeutic target to improve patient outcomes.